BRIEF published on 11/04/2025 at 11:35, 10 months 21 days ago Advicenne submits Sibnayal® to the US FDA FDA Advicenna Sibnayal® Renal Tubular Acidosis Registration Filing
PRESS RELEASE published on 11/04/2025 at 11:30, 10 months 21 days ago Inside Information / Other news releases Advicenne submits registration application for Sibnayal® in dRTA treatment to US FDA, designated orphan drug. Evaluation process expected to take 12 months Advicenne Sibnayal® US FDA DRTA Treatment Registration Application
BRIEF published on 09/19/2025 at 18:05, 1 year ago Advicenne: Half-year results in 2025 and outlook Financial Results Outlook Turnover United States Sibnayal®
BRIEF published on 07/28/2025 at 07:35, 1 year 1 month ago Advicenne Secures Marketing Authorization for Sibnayal® in Saudi Arabia Saudi Arabia Advicenne Reimbursement Sibnayal® DRTA
PRESS RELEASE published on 07/28/2025 at 07:30, 1 year 1 month ago Inside Information / Other news releases Advicenne obtains marketing authorization and reimbursement for Sibnayal® in Saudi Arabia, a fixed combination for rare kidney diseases, in collaboration with Taïba Healthcare Saudi Arabia Advicenne Reimbursement Marketing Authorization Sibnayal
BRIEF published on 07/25/2025 at 07:35, 1 year 2 months ago Advicenne Announces 9% Revenue Growth for H1 2025 Growth Turnover Advicenna Sibnayal® Pharmaceutical Markets
PRESS RELEASE published on 07/25/2025 at 07:30, 1 year 2 months ago Inside Information / Other news releases Advicenne reports H1 2025 sales of €2.6 million, with direct sales rising 17% and Sibnayal® sales in Europe up 90% compared to H1 2024. Company's cash flow horizon extends to Q3 2026 Cash Flow Pharmaceutical Advicenne Sibnayal H1 2025 Sales
BRIEF published on 07/21/2025 at 20:57, 1 year 2 months ago Advicenne raises 2.6 million euros to strengthen its financial capacity Capital Increase Financial Market Bpifrance Kidney Diseases Advicenna
BRIEF published on 03/27/2025 at 19:17, 1 year 5 months ago Advicenne Reports Solid Growth and Future Plans for 2025 Cash Flow Improvement 2025 Outlook Advicenne Financial Results Sibnayal Sales Growth ADV7103 Regulatory Progress
PRESS RELEASE published on 03/27/2025 at 19:12, 1 year 5 months ago Inside Information / News release on accounts, results Advicenne reports successful commercial performance of Sibnayal® in Europe, with total product sales up 9.4% to €4.9m. Major strides in US development with NDA filing expected in Q3 2025 Financial Results Advicenne Commercial Performance Sibnayal US Development
Published on 09/26/2026 at 01:00, 4 hours 35 minutes ago Guanajuato Silver Renews Base Shelf Prospectus
Published on 09/26/2026 at 01:00, 4 hours 35 minutes ago Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 7 hours 20 minutes ago Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 12 hours 5 minutes ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 14 hours 35 minutes ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/26/2026 at 00:01, 5 hours 33 minutes ago Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 18:30, 11 hours 4 minutes ago 029 Group SE: Publication of Half-Year Report 2026
Published on 09/25/2026 at 17:30, 12 hours 4 minutes ago GEVELOT S.A.: Weekly declaration of share buybacks – 09/25/2026 (French only)
Published on 09/25/2026 at 17:17, 12 hours 17 minutes ago Amendments to the Bond Terms and Conditions Have Been Implemented
Published on 09/25/2026 at 17:40, 11 hours 55 minutes ago Availability of the 2026 half-year financial report
Published on 09/24/2026 at 18:00, 1 day 11 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 1 day 11 hours ago GUILLEMOT CORPORATION: 2026 CONSOLIDATED INTERIM RESULTS
Published on 09/24/2026 at 17:45, 1 day 11 hours ago Cegedim first-half 2026 results: profitability continues to improve
